Supramolecular immunomodulatory hydrogelator potentiates CAR-T therapy with long-lasting endogenous immunity toward solid tumor eradication
Science Advances · 2026
DOI: 10.1126/sciadv.aee2120 ↗At a glance
Journal article in Science Advances, 2026. Written by Chenwei Jiang and 9 co-authors. Institution: School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200240, China. Major MEDLINE topics: Immunotherapy, Adoptive, Receptors, Chimeric Antigen, Hydrogels, Neoplasms. 52 references. The full text is freely available in PubMed Central. Funded by: National Natural Science Foundation of China, National Key Research and Development Program of China, Technology Commission of Shanghai Municipal China.
Abstract (original language)
The success of chimeric antigen receptor (CAR)-T cell therapy in hematologic malignancies has not been translated to solid tumors, primarily due to inadequate T cell infiltration and an immunosuppressive tumor microenvironment that drives T cell exhaustion. To address these challenges, we developed a tailored immunomodulatory drug-drug conjugate-based hydrogelator for the localized delivery of CAR-T cells targeting solid tumors. This hydrogel forms an in situ scaffold that serves as a sustained-release reservoir, enabling continuous co-delivery of CAR-T cells along with immunomodulatory agents—NLG919 (an IDO-1 inhibitor) and D PPA-1 (a PD-L1 antagonistic peptide)—to synergistically remodel the immunosuppressive tumor microenvironment and promote robust tumor recognition and elimination. Notably, this approach significantly enhances CAR-T cell infiltration and persistence, stimulates a potent endogenous tumor-specific immune response, while also establishing long-lasting immunological memory. In murine models of aggressive melanoma, metastatic breast cancer, and postoperative glioma, a single local administration of the hydrogel resulted in significant suppression of tumor growth, rechallenge, metastasis and recurrence. By integrating localized CAR-T cell delivery with in situ immune reprogramming, this system represents a versatile and clinically translatable platform that substantially improves the efficacy of CAR-T cell therapy against solid tumors.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200240, China.
- Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.
- School of Chemistry and Chemical Engineering, Shanghai Jiao Tong University, Shanghai 200240, China.
- School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China.
- Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou 310000, China.
ORCID profiles: Chenwei Jiang, Minglu Tang, Qi Shang, Qi Chen, Junjie Xie, Bing Feng, Feihu Wang
Funding
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Technology Commission of Shanghai Municipal China
- Key project at central government level: The ability establishment of sustainable use for valuable Chinese medicine resources
Cite
APA
Jiang, C., Tang, M., Guo, M., Shang, Q., Chen, Q., An, X., Xie, J., Zheng, K., Feng, B., & Wang, F. (2026). Supramolecular immunomodulatory hydrogelator potentiates CAR-T therapy with long-lasting endogenous immunity toward solid tumor eradication. Science Advances. https://doi.org/10.1126/sciadv.aee2120
Vancouver
Jiang C, Tang M, Guo M, Shang Q, Chen Q, An X, et al. Supramolecular immunomodulatory hydrogelator potentiates CAR-T therapy with long-lasting endogenous immunity toward solid tumor eradication. Science Advances. 2026. doi:10.1126/sciadv.aee2120
BibTeX
@article{Jiang2026,
author = {Jiang, Chenwei and Tang, Minglu and Guo, Mingmei and Shang, Qi and Chen, Qi and An, Xiaoran and Xie, Junjie and Zheng, Kangqi and Feng, Bing and Wang, Feihu},
title = {Supramolecular immunomodulatory hydrogelator potentiates CAR-T therapy with long-lasting endogenous immunity toward solid tumor eradication},
journal = {Science Advances},
year = {2026},
doi = {10.1126/sciadv.aee2120}
}
EUVIMED